Search
Close this search box.
×
Search
[custom_company_search_form]
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
97,819.25
(1.2%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
97,819.25
(1.2%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
97,819.25
(1.2%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
97,819.25
(1.2%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
97,819.25
(1.2%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
97,819.25
(1.2%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
97,819.25
(1.2%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
97,819.25
(1.2%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
97,819.25
(1.2%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
97,819.25
(1.2%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)

Stock Piper AI Index

Stock Piper AI Index

Subscribe
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
97,819.25
(1.2%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
97,819.25
(1.2%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
97,819.25
(1.2%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
97,819.25
(1.2%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
97,819.25
(1.2%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
97,819.25
(1.2%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
97,819.25
(1.2%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
97,819.25
(1.2%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
97,819.25
(1.2%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
97,819.25
(1.2%)
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)

Actinogen Medical Ltd

ACW

ASX

Actinogen Medical (ACW) is an ASX-listed, biotechnology company developing a novel therapy for neurological diseases associated with dysregulated brain cortisol. There is a well-established association between cortisol and detrimental changes in the brain, affecting cognitive function, harming brain cells, and contributing to long-term cognitive decline. Actinogen's therapeutic approach aims to regulate cortisol levels in the brain, potentially mitigating the negative effects of cortisol on cognitive function and promoting long-term neurological health.

Latest Posts

Line Chart with Gradient
Price
$0.026
0.002 (8.33%)
At Close 22/11 (AEST)
Related Companies
OPTHEA LIMITED
$OPT
LITTLE GREEN PHARMA LTD
$LGP
RACE ONCOLOGY LTD
$RAC
FIREBRICK PHARMA LIMITED
$FRE
RADIOPHARM THERANOSTICS LIMITED
$RAD

Leave a Comment on ACW


Comments for ACW

    Latest Posts

    actinogen-medical-asx-acw-secures-9m-rd-tax-rebate-acw
    Health Care $ACW
    Actinogen Medical (ASX: $ACW) secures $9m R&D tax rebateFunding bolsters financial runway and supports Alzheimer's clinical trial through mid-2026
    November 12, 2024
    actinogen-medical-asx-acw-reports-significant-progress-in-clinical-trials-acw
    Health Care $ACW
    Actinogen Medical (ASX: $ACW) reports significant progress in clinical trialsHighlights include advancements in Alzheimer's and depression trials, financial updates, and strategic changes
    October 30, 2024
    actinogen-asx-acw-leads-11-1-million-capital-raising-to-accelerate-xanamia-alzheimers-trial-acw
    Health Care $ACW

    Actinogen (ASX: $ACW) leads $11.1 million capital raising to accelerate XanaMIA Alzheimer's trial

    CEO Steve Gourlay invests $1 million to expedite XanaMIA Phase 2b/3 trial

    September 18, 2024
    actinogen-medical-asx-acw-pauses-trading-pending-further-announcement-acw
    Health Care $ACW

    Actinogen Medical (ASX: $ACW) pauses trading pending further announcement

    Trading temporarily halted awaiting additional news from the company

    September 16, 2024
    actinogen-medical-asx-acw-requests-trading-halt-for-capital-raising-and-share-purchase-plan-acw
    Health Care $ACW

    Actinogen Medical (ASX: $ACW) requests trading halt for capital raising and share purchase plan

    Company anticipates trading halt until announcement release or 18 September 2024

    September 16, 2024
    actinogen-asx-acw-announces-clinically-and-statistically-significant-benefits-in-depression-acw
    Health Care $ACW

    Actinogen (ASX: $ACW) announces clinically and statistically significant benefits in depression

    Xanamem® shows promising results in phase 2a XanaCIDD trial

    August 12, 2024
    actinogen-medical-asx-acw-releases-positive-xanamem-phase-2a-biomarker-trial-results-acw
    Health Care $ACW

    Actinogen Medical (ASX: $ACW) releases positive Xanamem® phase 2a biomarker trial results

    Xanamem® trial shows potential treatment effect in Alzheimer's disease patients

    July 22, 2024
    actinogen-medical-asx-acw-completes-oversubscribed-8-9m-capital-raising-acw
    Health Care $ACW

    Actinogen Medical (ASX: $ACW) completes oversubscribed $8.9m capital raising

    Entitlement offer closed with no shortfall, funding to progress XanaMIA trial in Alzheimer's disease

    May 30, 2024
    actinogen-medical-asx-acw-requests-trading-halt-for-fund-raising-announcement-acw
    Health Care $ACW

    Actinogen Medical (ASX: $ACW) requests trading halt for fund raising announcement

    Company requests halt pending announcement on fund raising

    May 1, 2024
    Unlocking the Future of Neurological Therapies: Actinogen Medical and the Xanamem® Breakthrough
    Health Care $ACW

    Unlocking the Future of Neurological Therapies: Actinogen Medical and the Xanamem® Breakthrough

    In the world of biotechnology, Actinogen Medical (ASX: ACW) is making waves with its innovative strides in neurological and neuropsychiatric research.

    March 22, 2024
    Tackling the Alzheimer’s Challenge: Actinogen Medical’s Xanamem® Promises Hope
    Materials $ACW

    Tackling the Alzheimer’s Challenge: Actinogen Medical’s Xanamem® Promises Hope

    Alzheimer's disease, a progressive neurological condition predominantly affecting older adults, continues to cast a shadow over the lives of millions worldwide

    March 22, 2024
    Select ACW Rises 20% : Discovering the Factors Driving to the Growth of Actinogen Medical ACW Rises 20% : Discovering the Factors Driving to the Growth of Actinogen Medical
    Materials $ACW
    ACW Rises 20% : Discovering the Factors Driving to the Growth of Actinogen MedicalActinogen Medical Ltd (ACW) has been attracting substantial attention in the volatile and unpredictable realm of financial markets
    March 22, 2024
    Actinogen Medical’s 2024 Roadmap: Converging Strategies for Growth
    Materials $ACW

    Actinogen Medical’s 2024 Roadmap: Converging Strategies for Growth

    Actinogen Medical has set a robust agenda for 2024, strategically aligning its priorities to steer the company towards growth and innovation

    March 21, 2024
    Actinogen Medical: Advancing the Fight Against Alzheimer’s and Beyond
    Materials $ACW

    Actinogen Medical: Advancing the Fight Against Alzheimer’s and Beyond

    Actinogen Medical (ASX: ACW) is a clinical-stage biopharmaceutical company pioneering a novel approach to treating neurodegenerative diseases and neuropsychiatric conditions

    March 21, 2024
    Actinogen Medical (ASX: $ACW) or Alto Neuroscience?
    Materials $ACW

    Actinogen Medical (ASX: $ACW) or Alto Neuroscience?

    In recent years, the world has started to pay more attention to mental health, recognising how important it is. Mental health issues, including problems with alcohol or drug use, are becoming more common, now affecting one in eight people worldwide.

    March 21, 2024
    actinogen-medical-asx-acw-progresses-two-phase-2-trials-acw
    Health Care $ACW

    Actinogen Medical (ASX: $ACW) progresses two phase 2 trials

    Advancing Xanamem® trials for Alzheimer's disease and depression

    February 26, 2024
    actinogen-medical-asx-acw-progresses-xanamem-clinical-trials-and-receives-rd-tax-incentive-rebate-acw
    Health Care $ACW

    Actinogen Medical (ASX: $ACW) progresses Xanamem clinical trials and receives R&D tax incentive rebate

    Advancing Alzheimer's and depression treatment trials, secures $4.8 million R&D tax incentive rebate

    February 26, 2024
    actinogen-medical-asx-acw-awarded-innovation-passport-for-xanamem-in-alzheimers-treatment-acw
    Health Care $ACW

    Actinogen Medical (ASX: $ACW) awarded innovation passport for xanamem in alzheimer's treatment

    MHRA approval accelerates pathway for Xanamem in Alzheimer's treatment

    February 16, 2024
    Xanamem: Illuminating Hope in Neurological Therapeutics
    Materials $ACW

    Xanamem: Illuminating Hope in Neurological Therapeutics

    In the intricate tapestry of neurological research, Xanamem emerges as a beacon of hope, offering a transformative once-a-day treatment with a unique, non-amyloid/non-tau mechanism.

    March 22, 2024

    ACW

    $ACW

    Actinogen Medical (ASX: $ACW) secures $9m R&D tax rebate

    Funding bolsters financial runway and supports Alzheimer's clinical trial through mid-2026

    ACW

    $ACW

    Actinogen Medical (ASX: $ACW) reports significant progress in clinical trials

    Highlights include advancements in Alzheimer's and depression trials, financial updates, and strategic changes

    ACW

    $ACW

    Actinogen (ASX: $ACW) leads $11.1 million capital raising to accelerate XanaMIA Alzheimer's trial

    CEO Steve Gourlay invests $1 million to expedite XanaMIA Phase 2b/3 trial

    ACW

    $ACW

    Actinogen Medical (ASX: $ACW) pauses trading pending further announcement

    Trading temporarily halted awaiting additional news from the company

    ACW

    $ACW

    Actinogen Medical (ASX: $ACW) requests trading halt for capital raising and share purchase plan

    Company anticipates trading halt until announcement release or 18 September 2024

    ACW

    $ACW

    Actinogen (ASX: $ACW) announces clinically and statistically significant benefits in depression

    Xanamem® shows promising results in phase 2a XanaCIDD trial

    ACW

    $ACW

    Actinogen Medical (ASX: $ACW) releases positive Xanamem® phase 2a biomarker trial results

    Xanamem® trial shows potential treatment effect in Alzheimer's disease patients

    ACW

    $ACW

    Actinogen Medical (ASX: $ACW) completes oversubscribed $8.9m capital raising

    Entitlement offer closed with no shortfall, funding to progress XanaMIA trial in Alzheimer's disease

    ACW

    $ACW

    Actinogen Medical (ASX: $ACW) requests trading halt for fund raising announcement

    Company requests halt pending announcement on fund raising

    ACW

    $ACW

    Unlocking the Future of Neurological Therapies: Actinogen Medical and the Xanamem® Breakthrough

    In the world of biotechnology, Actinogen Medical (ASX: ACW) is making waves with its innovative strides in neurological and neuropsychiatric research.

    Load More
    No More Posts
    Related Companies
    VECTUS BIOSYSTEMS LIMITED
    $VBS
    AVECHO BIOTECHNOLOGY LIMITED
    $AVE
    CAMBIUM BIO LIMITED
    $CMB
    RADIOPHARM THERANOSTICS LIMITED
    $RAD
    IDT AUSTRALIA LIMITED
    $IDT

    ASX News, First
    & Fast.

    By clicking Subscribe, you agree to our Terms & Conditions

    ASX News, First And Fast.

    By clicking Subscribe, you agree to our Terms & Conditions
    © 2024 Stock Piper.
    All rights reserved

    Blog

    Healthcare
    Materials
    Real Estate
    Consumer Staples
    Consumer Discretionary Brief
    Utilities

    Company

    About us
    Terms of use
    Privacy Policy

    Support

    Contact Support

    Socials

    Facebook
    Twitter
    LinkedIn
    © 2024 Stock Piper. All rights reserved

    Blog

    Healthcare
    Materials
    Real Estate
    Consumer Staples
    Consumer Discretionary Brief
    Utilities

    Company

    About us
    Terms of use
    Privacy Policy

    Support

    Contact Support
    © 2024 Stock Piper. All rights reserved
    Social Media Auto Publish Powered By : XYZScripts.com
    Stock Piper AI Index
    Subscribe
    Join FREE Newsletter

    Stock Piper AI Index Coming Soon!

    Join our Newsletter to gain exclusive insight and be notified once we are live.

    By clicking Subscribe, you agree to our Terms & Conditions

    ASX News, First And Fast.

    Get all the latest market updates straight to your inbox.

    By clicking Subscribe, you agree to our Terms & Conditions